SCHEMBL1407421

SCHEMBL1407421

O=C(c1ccc(F)cc1)c1cccc(C(F)(F)F)c1F

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.45
KAT6A Q92794 2/20 0.45
CTSS P25774 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
PLOD2 O00469 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
LTA4H P09960 1/20 0.41
P2RX7 Q99572 4/20 0.40
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
CDK2 P24941 1/20 0.39
KCNK3 O14649 1/20 0.38
KCNK9 Q9NPC2 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1125117 0.88 KAT6A (0.52) HDAC8KAT6ACTSSTAS1R3TAS1R1
SCHEMBL29941229 0.88 KAT6A (0.52) HDAC8KAT6ACTSSTAS1R3TAS1R1
SCHEMBL28188796 0.86 KAT6A (0.51) HDAC8KAT6ACTSSTAS1R3TAS1R1
SCHEMBL1407322 0.83 KMT2A (0.52) HDAC8LMNASMN1; SMN2
SCHEMBL3505889 0.78 HDAC8 (0.44) HDAC8KAT6ACTSSTAS1R3TAS1R1
SCHEMBL8553845 0.78 CYP1A2 (0.46) LMNAGAANR1H2SMN1; SMN2
SCHEMBL12869592 0.78 AKR1C3 (0.42) LMNAGAALTA4HCES2CES1
SCHEMBL398909 0.77 KAT6A (0.54) HDAC8KAT6ACTSSTAS1R3TAS1R1
SCHEMBL9560994 0.77 KAT6A (0.50) HDAC8KAT6ACTSSTAS1R3TAS1R1
SCHEMBL29286568 0.76 KAT6A (0.42) HDAC8KAT6ACTSSTAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
CN-101213194-A Indazoles useful in treating cardiovascular diseases WYETH CORP (US) 2008-07-02 CN disclosed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP disclosed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 HDAC8 571/4885KAT6A 1041/4885CTSS 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.